This Is MS Multiple Sclerosis Knowledge & Support Community

#ECTRIMS2021: EBV as a therapeutic target

https://multiple-sclerosis-research.org ... us-effect/


Conclusions: Preliminary data indicate ATA188 is well tolerated. Sustained EDSS improvement drove SDI in most pts, and in all but 1 pt, SDI was maintained at all subsequent timepoints. As a biomarker associated with disability, pts with sustained EDSS improvement (vs those without) showed greater increases in MTR signal at 12m, which may be suggestive of remyelination. The Phase 2 portion of this study, EMBOLD (NCT03283826), is ongoing and currently enrolling.

Gavin Giovannoni wrote: “We are talking with Moderna but their EBV vaccine is behind their CMV vaccine in priority and it needs to be tested in phase 1 first.”

Comment: BioNTech is already working on an MS vaccine. Perhaps they would prioritize work on a EBC vaccine.

thanks !!